Navigation Links
IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
Date:6/2/2008

mortality rate and represents the leading cause of cancer death in the United States. According to the American Cancer Society, approximately 213,000 new lung cancer cases will be diagnosed in the United States in 2007, and an estimated 160,000 patients will die from lung cancer. The American Cancer Society also estimates that non-small cell lung cancer represents 87 percent of all lung cancers.

In the European Union, non-small cell lung cancer represents 75 percent of all lung cancer. In addition, approximately 130,000 new cases will be diagnosed in 2007 in the top five markets (France, Germany, Italy, UK & Spain)

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's current views of future events including statements regarding the Phase 2 IDM-2101 study, the support that the survival data and positive safety profile and immunological data from the Phase 2 IDM-2101 provides for further clinical evaluation of IDM-2101, the potential for IDM-2101 as a treatment for non-small cell lung cancer and the Company's plans to evaluate strategic alternatives. Act
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) ... received a written notice (the "Notice") executed by the ... of the Company, requesting that the Board of Directors ... for stockholder action by written consent relating to the ... director seat resulting from Ronald J. Kanterman,s departure (the ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... KNOXVILLE, Tenn., Dec. 15 Medical researchers ... attention with their revolutionary new technology for a ... ,, Following the success of its ... filed a patent on the biomarker, CA11-19, and ... inexpensive blood test, ColoMarker(TM) will detect colon cancer ...
Breaking Medicine Technology:KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2Stanford study recommends change in treating pulmonary embolisms 60161 1Stanford study recommends change in treating pulmonary embolisms 60161 2Stanford study recommends change in treating pulmonary embolisms 60161 3Stanford study recommends change in treating pulmonary embolisms 60161 4Vegetables can protect unborn child against diabetes 10545 1Vegetables can protect unborn child against diabetes 10545 2Stanford researchers awarded 246 27 million to study energy efficiency and human behavior 10541 1Stanford researchers awarded 246 27 million to study energy efficiency and human behavior 10541 2
(Date:12/16/2009)... 16 Medizone International, Inc. (OTC Bulletin ... of Directors and the Board of Medizone New ... International Inc. holds a 50% interest, agreed on ... and reconvey to Medizone International all global marketing ... International,s Chairman, Edwin G. Marshall said, "Time has ...
(Date:12/16/2009)... Study finds 6- to 11-month interval lessens complication risks , , ... bundle of joy has had such a profound impact on ... take a breath. A new study suggests that you ... pregnant again, and that more than 11 months could be ... interval between pregnancies was less than six months, the chances ...
(Date:12/16/2009)... 16 /PRNewswire-FirstCall/ - TSO3 Inc. ("TSO3") (TSX: TOS) ... has been reached for 3M to be the ... Sterilizer. The partnership with TSO3, an innovator in ... healthcare settings through the use of ozone, will ... through 3M,s global sales channel. This agreement, combined ...
(Date:12/16/2009)... engaged in the development of products that help survivors of ... mobility, announces the publication of an interview with the inventors ... (Advance for Physical Therapy and Rehab Medicine, vol. 20, issue ... , ... (PRWEB) December 16, 2009 -- ...
(Date:12/16/2009)... of buying another product or thing for your loved ones this ... personal assistant services like housekeeping, errand running, child care, and pet ... ... December 12, 2009 -- Residents of the Denver and Boulder metro ... to their friends and loved ones by using Delegate Source,s " ...
Breaking Medicine News(10 mins):Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 3
... emission tomography (PET) imaging with bioluminescencethe light produced by ... understand the behavior of transplanted or implanted stem cells ... treatments for disease. , According to a study ... found that using the unique combination of noninvasive PET ...
... 6 A Canadian research team led by ... Columbia, Vancouver has,determined that there are significant changes ... instead of a standard exercise bicycle.,This research offers ... date on,the positive health and fitness effects of ...
... Medicaid Generic Prescription,Drug System, FRANKFORT, Ky., Dec. ... press conference at Capital Pharmacy and,Medical Equipment urging ... ensure S.1951, the Fair Medicaid Drug Payment Act ... a vote before they adjourn this year.,The bill ...
... ready to attend,holiday parties, it,s time for parents to ... alcohol. Teens are constantly exercising their,independence and individuality, and ... chances are your teens will be too., Even ... guarantees.,According to a study last year by The National ...
... busiest shopping time of the year. In fact, more than ... this year according to a survey by the National Retail ... to the shopping trends. , One such economist, Dr. ... author of The Personality Continuum and Consumer Behavior, has taken ...
... Medical research has revealed much about cancer prevention, but ... acting on it" Today, at the American Association ... in Cancer Prevention Research, being held from December 5 ... of how best to translate cancer prevention science into ...
Other Medicine News:Health News:PET and bioluminescent imaging aid evaluation of stem cells' potential for new ways to treat disease 2Health News:PET and bioluminescent imaging aid evaluation of stem cells' potential for new ways to treat disease 3Health News:University of British Columbia Research Shows Health Benefits of GameBike (TM) 2Health News:Kentucky Pharmacists Urge Senator McConnell to Put Patients First 2Health News:Kentucky Pharmacists Urge Senator McConnell to Put Patients First 3Health News:This Holiday Season, Teach Your Kids the Science of How Drinking Alcohol Can Hurt Them 2Health News:This Holiday Season, Teach Your Kids the Science of How Drinking Alcohol Can Hurt Them 3Health News:Public health and cancer prevention: Success and future challenges in cancer policy 2Health News:Public health and cancer prevention: Success and future challenges in cancer policy 3Health News:Public health and cancer prevention: Success and future challenges in cancer policy 4Health News:Public health and cancer prevention: Success and future challenges in cancer policy 5Health News:Public health and cancer prevention: Success and future challenges in cancer policy 6Health News:Public health and cancer prevention: Success and future challenges in cancer policy 7
Hypervisor III Central Monitoring System...
... Central Monitoring System combines Invivo's AutoNet™ ... central monitoring and clinical information system ... monitoring features, including alarms, full disclosure ... connecting your patient to a bedside ...
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... List Editor) Multi-Channel Infusion System brings a ... instrument combines three independent infusion channels with ... unparalleled small size. Now with Advanced Dose ... simplifies the delivery of complex drug regimens. ...
Medicine Products: